72results about How to "Effective immune response" patented technology

A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40 ligand, SEQ ID NO:1 and SEQ ID NO: 2, respectively, or its homotrimer, CD40LT. The DNA vaccine can be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier. In a method embodiment, the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells. A preferred method embodiment includes the additional step of treating the mammal with recombinant antibody fusion protein huKS1/4-IL2 to enhance the immune response effectiveness of the vaccine.

The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.

A method of treating tumor tissue of an individual is provided. The method is effected by applying to cells of the tumor tissue electrical field pulses having a strength, a repetition frequency and a pulse width selected capable of inducing endocytosis mediated cell death thereby treating the tumor tissue.

The present invention relates to methods and compositions for vaccinating pigs against porcine circovirus associated diseases.

Described herein, are microneedle devices comprising a recombinant alphavirus replicon encoding an exogenous polypeptide, wherein the recombinant alphavirus replicon is coated onto or embedded into a plurality of microneedles. Also described herein are methods of preparing a microneedle device comprising a recombinant alphavirus replicon encoding an exogenous polypeptide. Also disclosed herein are methods of inducing an immune response in an individual comprising contacting the individual with a microneedle device comprising a recombinant alphavirus replicon encoding an exogenous polypeptide.

The safe mixed feed for aquatic animal includes base feed and added compound microecological preparation in the amount of 0.02-0.05 wt% of the base feed. The compound microecological preparation is mixture of fissiparous vibrio and bacillus in the weight ration of 1 to 1-2. The safe mixed feed can raise the immunity of aquatic animal, reduce diseases and raise survival rate obviously.

The present invention is directed to pharmaceutical compositions that contain a combination of apolipoprotein E and an antigenic lipid. The compositions may be administered to a subject for the purpose of inducing an immune response against the lipid and in immunization protocols.

The present invention discloses one kind of adjuvant for pig vaccine and its preparation process and constituted pig vaccine. The gene adjuvant for pig vaccine is adjuvant including pig interleukin-6 gene (pIL-6), or recombinant plasmid pcDNA-pIL-6 of animal cell expression plasmid pcDNA3.1 and pig interleukin-6 gene (pIL-6). The pig vaccine is composition of pigí»s cysticercus-resisting vaccine composition; pigí»s deactivated foot-and-mouth disease virus vaccine and the gene adjuvant. The gene adjuvant of the present invention is prepared through gene cloning, recombination, recombinant plasmid proliferation, extraction and purification and other processes.

The invention relates to a PCV3Cap protein epitope peptide, an anti-PCV3Cap protein monoclonal antibody, and a preparation method and application thereof. The invention provides the anti-PCV3Cap protein monoclonal antibody, and further provides a heavy chain variable region sequence and a light chain variable region nucleotide and amino acid sequence of the monoclonal antibody. On the basis, the antibody can be prepared by a genetic engineering method; and meanwhile, modification such as addition, deletion and replacement of one or more amino acids can be performed by genetic engineering and protein engineering methods to obtain an active fragment or a conservative variant thereof, thereby laying a foundation for further improving the specificity and affinity of the antibody. The antibody has relatively high specificity, has no cross reaction with PCV1, PCV2 and other porcine viruses such as CSFV, PRRSV and PRV, and has wide research and application values and commercial use values in immunological detection such as antigen/antibody detection kits, antigen/antibody immunochromatographic test paper, IFA, IPMA and Western Blotting.

The invention provides rBCG for expression of Br. Melitensis P39 and L7/L12 fusion gene. The rBCG is constructed by transferring an expression vector carrying codon-optimized Br. Melitensis P39 and L7/L12 fusion gene into BCG. Brucellosis-generated cytoplasm binding protein PBP39 (coding gene is P39) and Brucellosis ribosomal protein L7/L12 are both T-cell antigen. Bacillus Calmette-Guerin (BCG) vaccine is the only one commercial vaccine for preventing tuberculosis so far. The BCG vaccine has a remarkable immunologic adjuvant effect and is an exogenous gene expression host with good performance and high safety. By BCG expression of the codon-optimized Brucellosis P39 and L7/L12 fusion gene, expression quantity of the target gene can be increased. The rBCG vaccine can simulate intracellur infection and parasitic characteristics of Brucellosis to more effectively induce body to generate immune response, can perform advantages of high safety, simple preparation, low cost, etc. of BCG as the expression host as well as the immunologic adjuvant effect of the BCG itself, and is expected to become a novel Brucellosis vaccine.

The invention provides a microemulsion-based vaccine delivery system, and also provides a preparation method and application thereof. According to microemulsion in the invention, a series of metal ioncompounds are adsorbed; and antigens are added in a preparation process, so that antigen entrapment can be realized and a stable vaccine preparation is obtained. The vaccine prepared by the inventioncan be efficiently taken in by antigen presenting cells, effectively transferred to lymph nodes and induce antigen-specific immune response, and has a wide application prospect.

An attenuated Salmonella typhi carrier vaccine carrying tubercular mycobacterium Ag85B is prepared through preparing prokaryotic recombinant expression plasmid pGEX-Ag85B, configuring eukaryotic recombinant expression plasmid pVAX1-Ag85B, and preparing said antitubercular vaccine. It can be orally taken.

The invention discloses a construction method of a multivalent epitope and subunit vaccine, and belongs to the field of vaccines. An antigen protein is connected to two ends of LTB26 through fusion expression to obtain a fusion protein, and a pentamer of the fusion protein is obtained by means of the characteristic that LTB26 can be self-assembled to form a pentamer. The active ingredient of the vaccine is the pentamer of the fusion protein. The vaccine is rich in immunogen quantity and variety, and the activity of a LTB26 immunologic adjuvant and the immunogen activity of an antigen peptide are combined together, so that the vaccine can stimulate an organism to generate a large number of specific antibodies, effective immune response is stimulated, and a procedure of adding an immunologicadjuvant is omitted. The protein fused to two ends of LTB26 can also be other proteins other than an antigen protein, and can be applied to the fields other than vaccine preparation, such as large-scale preparation of antibodies, research and development of medical detection kits, and the like.

The invention discloses a preparation method of a nano vaccine with pH and reduction double sensitivity and an obtained product. The nano vaccine is obtained by taking PEI-modified mesoporous silica nanospheres as a raw material, adsorbing a model antigen through electrostatic interaction, and then wrapping an outer layer with a metal phenolic network with reduction sensitive disulfide bonds as aprotection network. The preparation method is simple and convenient to operate, low in energy consumption, environment-friendly and easy to expand production, and the obtained nano vaccine has very good in-vivo long-term stability and biocompatibility and has remarkable treatment and prevention effects on tumors.

The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.

The invention belongs to the field of biomedicines and relates to an anti-hyperlipidemia protein vaccine aiming at PCSK9 (Proprotein convertase subtilisin/kexin type 9). Aiming at solving the technical problems, the anti-hyperlipidemia protein vaccine which has good performances and takes the PCSK9 as a target is researched and developed. The protein vaccine aiming at the PCSK9, which is prepared by the invention, can be used for remarkably lowering the level of blood lipid of serum and has remarkable immunogenicity and good safety; a preparation method is simple and feasible and is low in cost. The protein vaccine aiming at the PCSK9 can be used for preventing and treating hyperlipidemia diseases and can realize treatment effect without the need of completely blocking the PCSK9; a condition that individuals is intolerant to complete blocking of the PCSK9 is avoided and the anti-hyperlipidemia protein vaccine has a better application prospect.

The invention discloses an escherichia coli engineering bacterium for synthesizing glycoprotein conjugate vaccines for neonatal meningitis escherichia coli and application, and relates to a method forconstructing a cell factory for synthesizing O1 serum type glycoprotein conjugate vaccines for neonatal meningitis escherichia coli. O1 antigens are constructed based on a DNA Assembler method by utilizing efficient homologous recombination efficiency of saccharomyces cerevisiae so as to synthesize gene cluster plasmids; the O1 antigens are converted in escherichia coli JM109 to synthesize gene cluster shuttle plasmids, and the plasmids are identified by virtue of lipopolysaccharide extraction, gel electrophoresis and silver staining; waaL and wecA in the JM109 are deleted with the aid of FLP-FRT so as to eliminate the interference of original incomplete O antigens; and pET28a(+) plasmids are reconstructed and induced to synthesize the glycoprotein conjugate vaccines, the glycoprotein ispurified by virtue of an AKTA Primeplus protein purification workstation, and the glycoprotein is identified by virtue of western-blotting. The constructed recombinant escherichia coli provides a novel idea for synthesizing the glycoprotein conjugate vaccines by a biological method.

The invention discloses construction and application of genetically engineered escherichia coli of a group of extraintestinal pathogenic escherichia coli glycoprotein conjugate vaccines On the basis of CRISPR-cas9, zwf, pfkB, lacZ, manA and pykA genes in an E.coli K-12 MG1655 strain are deleted, and strains capable of synergistically utilizing glucose and glycerol are constructed and are respectively used for synthesizing O antigen polysaccharides and maintaining physiological metabolism of bacteria. Further, waaL, enterobacterial common antigen(ECA) and O16 gene clusters are deleted, and a chassis cell is constructed as OSLA. O5 and O7 antigen synthesis gene clusters are respectively introduced, and besides, expression glycosyltransferase and carrier protein are introduced to synthesize various serotype glycoprotein conjugate vaccines. Animal immune experiments prove that purified glycoprotein can stimulate mice to generate antibodies with a protective effect, and the protection ratecan reach 90% or above. The recombinant escherichia coli glycoprotein conjugate vaccines constructed by the invention provide a new choice for immunotherapy against extraintestinal pathogenic escherichia coli infection.